Global RNA Targeting Small Molecule Drug Discovery Market 2026 – 2035

The market size of the global RNA targeting small molecule drug discovery will be estimated at USD 2.4 billion in 2025 and is expected to grow to between USD 2.9 billion in 2026 and about USD 17.6 billion by 2035 with a current CAGR of 22.1% during the period of 2026 to 2035.

The major players of this market are the increasing comprehension of RNA secondary and tertiary structures, which together allow for the rational design of small molecules capable of selectively binding the functional RNA motifs, as well as the presence of clinical proof-of-concept from approved and late-stage drugs that target RNA splicing or translation. Very fast development in enabling technologies—in particular those mentioned above, e.g., high-throughput RNA screening assays, structure-based drug design, and AI-based computational modeling—has greatly shortened the discovery timelines and facilitated the identification of hits.

Market Highlight

• North America had a market share of 61% and was the market leader in the RNA targeting small molecule drug discovery market in 2025.

• It is projected to have the highest CAGR of 6.0% across Asia Pacific in the years 2026-2035.

• By indication, the neurological diseases segment will dominate the market with over 40% in 2025.

• By end use, the pharmaceutical and biopharmaceutical companies held the largest revenue share of over 58% in 2025.

Significant Growth Factors

The RNA targeting small molecule drug discovery market trends present significant growth opportunities due to several factors:

• Significant Investments in Research and Development (R&D) by Pharmaceutical and Biotechnology Companies:

Investments in research and development (R&D) by pharmaceutical as well as biotechnology companies have a significant impact on the RNA-targeting small-molecule drug discovery market, as these investments are stimulating innovation, lowering scientific risk and broadening the pipeline of RNA-focused therapeutics. Leading pharmaceutical firms along with emerging biotech companies are investing significant dollar amounts to get a grasp of the RNA structure, dynamics, and function while also working on specialized screening platforms, AI‐enabled drug design tools, and structure‐guided medicinal chemistry capabilities tailored to RNA targets. This continuous R&D spending has led to the discovery of new RNA binding areas and disease‐related RNA processes, such as splicing regulation and RNA-protein interactions, that were previously labeled unapproachable by small molecules. Further, the greater R&D funding makes stronger the collaboration of RNA‐targeting small molecules from early discovery to preclinical and clinical development thus creating crucial proof-of-concept data that bring in more investment and strategic partnerships. As drug manufacturers strive to diversify their pipelines and meet unfilled medical needs, especially in the areas of cancer, brain disorders, and rare genetic diseases, R&D funding shifts to RNA-based methods that are capable of targeting "undruggable" areas. Therefore, the commitment to R&D by pharma and biotech companies is unambiguously pushing the market up, as they are improving the technological capabilities, increasing the clinical pipelines, and making RNA-targeting small-molecule drug discovery more commercially viable.

• Growing prevalence of neurological disease:

One major factor that drives the RNA-targeting small molecule drug discovery market is the increasing number of neurological diseases. This is because many of these disorders are caused by the same factors that are difficult to treat with the use of conventional therapies that target proteins such as RNA processing gone wrong, splicing mistakes and faulty genes. The conditions of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and Huntington’s disease are all pointing towards RNA-level failure as the major cause of disease development and the creation of strong demand for the therapies that can accurately modulate the RNA function.

Neurology's RNA-targeting small molecules are especially appealing since they can be created in such a manner that their penetration through the blood-brain barrier would be more effective than that of many biologics and nucleic acid-based therapies, therefore allowing immediate action within the central nervous system. As the aging population all over the world becomes the main contributor to the increasing burden of neurological diseases, the pharmaceutical and biotechnology companies are raising their efforts to develop small molecules that can modulate RNA such as the ones that can correct splicing defects, regulate RNA repeats that are toxic, or change the interactions of RNA with proteins in a way that they are related to the disease. The combination of unmet clinical needs that are beneficial from a drug-like point of view and the progress in the field of RNA biology is quickening the pace of research activities and investment, thus leading to the growth of the RNA-targeting small-molecule drug discovery market. For instance, as per the figure published by BMJ Group, by 2050, there will be 25.2 million people living with Parkinson’s disease worldwide (a 112% increase from 2021).

What are the Major Advances Changing the RNA Targeting Small Molecule Drug Discovery Market Today?

• High-throughput and Cell-Based RNA Screening Technologies: Technologies for high-throughput and cell-based RNA screening come as a big leap forward that alters the entire drug discovery process for small molecules targeting RNA, since these methods directly tackle one of the historical bottlenecks of the field, namely, the difficult but efficient identification of selective and functional RNA-binding compounds. RNA has always posed a problem for the traditional screening methods because of its structural flexibility and the complex nature of its behavior intracellularly. With modern high-throughput platforms, it is now possible for researchers to rapidly screen large libraries of compounds against specific RNA motifs, and in such cases, advanced cell-based assays are already being used to determine RNA engagement and its subsequent biological effects in a study environment that is physiologically relevant. These technologies yield better anatomical-activity relationships, amplify the hit-to-lead ratio, and speed up the elimination of early-stage candidates. Additionally, amongst the benefits of cell-based RNA screening methods is that they make functional readouts like splicing correction, translation modulation, and disruption of RNA–protein interactions available for the early validation of therapeutic relevance. The transition from simply biochemical assays to biologically significant screening has brought about a huge decrease in the risks of RNA-centric drug discovery programs. By the time the pharmaceutical and biotechnology companies have fully incorporated these platforms; not only will the discovery timelines be like years shorter, but the costs of development will also have been optimally managed, and the confidence in RNA-targeting small molecules will have been even stronger—thus, the market then grows ever faster and the clinical pipeline gets wider.

• AI and Computational RNA Drug Design: AI and computational RNA drug design are the new paradigms in the RNA-targeting small-molecule drug discovery market, as they take care of the problem of selecting the right target and the RNA's complex structure. The inability to get the exact conformation and the dynamic nature of the RNA molecules have thus posed difficulties for the traditional drug design methods based on the structure. However, AI- and machine learning-based models can now predict RNA secondary and tertiary structures accurately, discover druggable RNA binding pockets, and even simulate RNA-small-molecule interactions at an unprecedented speed and scale. These computational instruments greatly minimize the trial-and-error aspect of RNA drug discovery. Moreover, the AI-assisted platforms facilitate the hit identification and lead optimization processes by analyzing the widely available chemical libraries and linking the molecular characteristics with RNA binding affinity, selectivity, and pharmacokinetic properties. If combined with the experimental screening data, the computational RNA design then leads to better structure-activity relationships and lower attrition rates during the preclinical development phase. As more and more pharmaceutical and biotechnology firms are incorporated with the AI-driven RNA discovery platforms, the timeline of the development is getting shorter, the efficiency of R&D is getting better, and the commercial viability of the RNA-targeting small molecules is getting stronger. AI and computational design, therefore, have become the main factors for driving innovation and expansion in the market. For instance, In February 2025, the company Terrain Biosciences finally revealed itself to the public and straightaway took the position of the very first firm that deals with RNA to the satellite role of artificial intelligence and advanced manufacturing tech in the entire pharmaceuticals industry. This is done to speed up the progress of diversely treated medicines. Based in Cambridge, the startup has attracted $9 million in seed money from well-known investors like Magnetic Ventures, Bruker Corporation, and Ex Nihilo, along with the backing of biotech mavericks John Maraganore, Hans Bishop, and John Evans.

Category Wise Insights

By Indication

Why Neurological Diseases Lead the Market?

The neurological diseases segment will dominate the market with over 40% in 2025. Researchers have been intensively and continuously targeting RNA with therapeutic agents in the treatment of neurological disorders. The approach consists of developing small molecules to tackle repeat expansion disorders like Huntington’s Disease and Amyotrophic Lateral Sclerosis (ALS), and at the same time, moderating RNA splicing for conditions such as Spinal Muscular Atrophy (SMA). Apart from that, drug delivery to the brain has been made more effective and AI is becoming a great help in the identification of targets and design of drugs, thus promising more precise and efficacious treatment of neurological diseases stemming from RNA dysfunction. For example, together with Skyhawk Therapeutics, Ipsen in April 2024, made an announcement to the effect that they would be collaborating, among other things, to create and develop small-molecule drugs that are able to target an area of RNA related to rare neurological diseases. The partnership included an Ipsen option to acquire exclusive global rights for two development candidates.

The cancer segment is expected to grow at the highest CAGR over the projected period. The growing collaboration among the key market players for the innovative solution in the oncology field drives the sector growth. For instance, in December 2024, Rgenta Therapeutics, the biotech company that is at the forefront of the development of a new class of oral small molecules that target RNA for the treatment of cancer and neurological disorders, reported that it has struck a multi-year, multi-target strategic research partnership with GSK. The objective of the partnership is to facilitate the discovery and development of new RNA-targeted small-molecule splice modulators for various diseases, including cancer.

By End Use

Why Pharmaceutical and Biopharmaceutical Companies Dominates the RNA Targeting Small Molecule Drug Discovery Market?

The pharmaceutical and biopharmaceutical companies held the largest revenue share of over 58% in 2025. The growing collaboration for the treatment of diseases like cancer flourishes the market growth. For instance, in June 2024, ReviR Therapeutics, a company engaged in biotechnology and focused on small molecule RNA splicing modulators for neurogenetic diseases and oncology, and Asieris Pharmaceuticals, a leading global biopharma company in the area of genitourinary tumors and related diseases, today proclaimed the attainment of a milestone in their partnership. The focus on novel targets for cancer treatment has led to the successful discovery of a new lead series of small molecules, which are capable of reversing the expression of an oncogenic driver gene. The molecules were identified through ReviR's exclusive VoyageR AI platform that has the potential to transform the process of drug discovery in several diseases, including the area of genitourinary cancers.

The academic and research institutes segment is expected to grow at the highest rate over the projected period. Research and academic institutions are assuming an important and progressively revenue-generating role in the RNA-targeting small-molecule drug discovery market, mainly via funded research programs, licensing of intellectual property (IP), and translational collaborations with pharmaceutical and biotech companies. The growth in revenue for this segment is fueled by the increased public and private research funding aimed at RNA biology, which is comprised of grants for RNA structure elucidation, splicing regulation, and RNA-protein interaction studies, among others. As RNA has become a recognized therapeutic target, the academic community is able to obtain larger multi-year funding awards and is also able to create and grow the dedicated RNA research centers, which thus leads to an increase in the research revenues.

Report Scope

Regional Analysis

How Big is the North America RNA Targeting Small Molecule Drug Discovery Market Size?

Its market size, in terms of North America RNA targeting small molecule drug discovery, is projected to be USD 1.5 billion in 2025 with a growth of about USD 8.5 billion in 2035 with a CAGR of 18.9% between 2026 and 2035.

Why did North America Dominate the RNA Targeting Small Molecule Drug Discovery Market in 2025?

In 2025, North America will dominate the global market with an estimated market share of 61%. Advanced pharmaceutical ecosystem of the region, the high investments in research and development, and the early adoption of innovative drug discovery technologies are what mainly drive the growth. The U.S., which is the main contributor, has a pretty heavy presence of most of the world's big pharmaceutical companies, small biotech firms focusing on RNA research, the top academic research institutions that are willing to cooperate the most in RNA biology and small-molecule discovery. These companies are pouring large amounts of money into high-throughput screening platforms, AI-aided computational RNA design, and translational research programs which result in faster discovery of new drugs and their availability for testing in clinics, thus increasing the number of candidates in the pipeline.

U.S. RNA Targeting Small Molecule Drug Discovery Market Trends

The US is expected to lead the RNA targeting small molecule drug discovery market over the analysis period. The country's growth is owing to the rising prevalence of the neurological disorders. Moreover, the presence of major players and continuous launch of innovative solutions drives the U.S. RNA targeting small molecule drug discovery market. For instance, in August 2025, Skyhawk Therapeutics, Inc., which is at the forefront of the discovery and development of small molecules that regulate RNA expression, made a public announcement regarding a research collaboration with Merck KGaA, Darmstadt, Germany that is of strategic importance. The partnership will be directed toward the identification of new small molecules that target RNA in certain brain diseases with a high unmet medical need.

Why is Asia Pacific Experiencing the Fastest Growth in the RNA Targeting Small Molecule Drug Discovery Market?

The Asia Pacific region is expected to grow at the highest CAGR of 6.0% during the projected period. The strengthening healthcare sector, rising investments in research and development, and chronic disease burden are the major factors driving the market growth in the region. The presence of a huge patient population along with the medical needs not being met are additional factors contributing to the market growth. Measures taken by the government to support drug discovery and development, along with the growing awareness of RNA-targeted therapies, will in turn be the factors causing the growth of the market in the Asia Pacific region.

India RNA Targeting Small Molecule Drug Discovery Market Trends

The Indian market has an extremely fast-growing market. The vast number of patients in the Indian market, along with the increasing healthcare spending and the rising number of clinical trials for RNA-targeted therapies, are all factors driving the Indian market. In addition, the nation’s burgeoning pharmaceutical sector and the presence of proficient researchers are also playing a role in the growth of the market.

Why is Europe is growing at a significant rate in the RNA Targeting Small Molecule Drug Discovery Market?

Europe holds a significant market share over the projected period. Increasing government initiatives in support of research and development in RNA-targeted therapies, personalized medicine as a major area of focus, and the higher rate of chronic diseases all fuel this trend. The collaboration between pharmaceutical companies and academic institutions is another factor that promotes market growth. The existence of a qualified workforce and state-of-the-art research infrastructure are also factors that give the Europe market of RNA-targeting small molecule drug discovery a strong position.

Germany RNA Targeting Small Molecule Drug Discovery Market Trends

Germany holds the dominant position in the Europe market. The development has been made possible by a robust research infrastructure, a large number of pharmaceutical and biotechnology firms, and a growing government grant for RNA research. The aging population of the country and the consequent increase in age-related diseases are also factors that make the demand for innovative therapies, such as RNA-targeting small-molecule drugs, higher.

Why is the Middle East & Africa Region is growing rapidly in the RNA Targeting Small Molecule Drug Discovery?

The MEA region is growing at a steady rate over the projected period. The development of the region is supported by the factors of escalating investments in the biomedical field, the increase of hospital and clinic facilities, and the rising interest in personalized medicine throughout certain countries in the Middle East and Africa (MEA). Also, the governments and health institutions in the Middle East, especially in the countries making up the Gulf Cooperation Council (GCC), are emphasizing life sciences research as a component of their economic diversification plans, thus resulting in more money for genomics, RNA biology, and drug discovery research that employs cutting-edge techniques. As a result, the academic institutions, research facilities, and biotechnology startups that are working on RNA-based therapeutics are all benefiting from this situation.

UAE RNA Targeting Small Molecule Drug Discovery Market Trends

UAE is growing rapidly over the projected period driven by the country's strategic emphasis on life sciences, genomics, and cutting-edge health care innovation.

Top Players in the RNA Targeting Small Molecule Drug Discovery Market and Their Offerings

• ACCENT THERAPEUTICS

• LES LABORATOIRES SERVIER

• Arrakis Therapeutics

• AstraZeneca

• Epics Therapeutics

• Expansion Therapeutics

• F. Hoffmann-La Roche Ltd

• PTC Therapeutics Inc.

• Ribometrix

• Anima Biotech Inc.

• Skyhawk Therapeutics

• Others

Key Developments

RNA targeting small molecule drug discovery market has experienced considerable changes in the last two years as the market players are trying to diversify their technological aspects and develop product portfolios using strategic approaches.

• In June 2025, Reborna Biosciences, Inc., a firm that primarily works on the production of remarkable drugs for tough medical situations and the disclosure of rare genetic diseases, has successfully raised 770 million yen through the issuance of shares aimed at a specific group of investors. The money has been provided by both present and future investors. (https://rebornabiosciences.com/en/news/16210)

These strategic measures have enabled the companies to reinforce their competitive positions, increase the product line, boost their technological competencies and also seize growth opportunities in the fast-growing RNA targeting small molecule drug discovery market.

The RNA Targeting Small Molecule Drug Discovery Market is segmented as follows:

By Indication

• Cancer

• Metabolic Diseases

• Infectious Diseases

• Neurological Diseases

• Others

By End Use

• Academic and Research Institutes

• Pharmaceutical and Biopharmaceutical Companies

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America